What is the preferred duration of adjuvant aromatase inhibitor therapy in patients with triple positive breast cancer?
Does node positivity affect your decision? Is there a role for predictive/prognostic test?
Community PollStarted
What is your preferred duration of adjuvant aromatase inhibitor therapy in patients with triple positive breast cancer?
31 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet MemberInvited Expert
Medical Oncology · H Lee Moffitt Cancer Center, University of South Florida
Answered on
The preferred duration in ER+PR+/-HER2+ disease for adjuvant aromatase inhibitors is not specifically defined in guidelines separate from ER+ disease in general. An older study looking at recurrence patterns across HER2+ disease (Park et al., PMID 19956951) showed ER+HER2+ disease had more delayed r...
Join for free or sign in to see the full answer